Revolution Medicines (NASDAQ:RVMD) Sees Unusually-High Trading Volume – Still a Buy?

Revolution Medicines, Inc. (NASDAQ:RVMD) saw unusually-strong trading volume on Wednesday . Approximately 2,357,874 shares traded hands during mid-day trading, a decline of 30% from the previous session’s volume of 3,348,162 shares.The stock last traded at $149.0580 and had previously closed at $147.01.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: M&A interest remains a potential upside: commentators say RVMD still looks like an attractive takeover target after positive daraxonrasib data, which could support a takeover premium or strategic interest. Why Revolution Medicines still looks like a prime takeover target
• Positive Sentiment: Bullish clinical/analyst commentary: some analysts and commentators are calling a “Strong Buy” based on daraxonrasib trial wins and pipeline expansions, supporting the view that clinical progress can drive long-term value. Revolution Medicines: ‘Strong Buy’ On Daraxonrasib Win
• Positive Sentiment: Analyst support: Wedbush reaffirmed an “Outperform” rating, signaling continued institutional bullishness despite near-term noise. Revolution Medicines ‘Outperform’ Rating Reaffirmed at Wedbush
• Neutral Sentiment: Minor estimate tweak: LifeSci Capital marginally adjusted its Q4 2026 EPS estimate (from –$2.09 to –$2.08), which is effectively immaterial to near‑term market moves but reflects continued analyst monitoring of spend and development timelines.
• Negative Sentiment: Large concurrent financing upsized to ~ $2.0B (≈10.56M shares at $142 + $500M 0.50% convertible notes) — proceeds earmarked for R&D/commercialization but the deal increases share count and creates dilution risk; convertible terms include an initial conversion price ~ $198.80 (~40% premium to the equity price). Settlement and underwriter option can further increase float, pressuring the stock. Revolution Medicines Prices $2.0 Billion in Concurrent Upsized Offerings
• Negative Sentiment: Analyst cuts from HC Wainwright: multiple downward revisions to quarterly and FY2026 EPS (notably a larger FY downgrade) signal concern about near-term profitability and raise caution on operating-cost and timeline assumptions.
• Negative Sentiment: Insider selling and mixed institutional flows: filings show substantial insider sales and notable portfolio rebalancing by large institutions, which can add selling pressure and amplify volatility. QuiverQuant: Revolution Medicines Announces Pricing of Offerings

Wall Street Analysts Forecast Growth

RVMD has been the topic of a number of analyst reports. Benchmark restated an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. UBS Group assumed coverage on shares of Revolution Medicines in a research report on Friday, February 27th. They set a “buy” rating for the company. Evercore reiterated an “outperform” rating on shares of Revolution Medicines in a research note on Tuesday. Wedbush reissued an “outperform” rating on shares of Revolution Medicines in a report on Tuesday. Finally, Truist Financial upgraded Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, March 25th. Four analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $78.94.

Revolution Medicines Price Performance

The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The company’s 50 day simple moving average is $102.10 and its 200 day simple moving average is $85.20. The company has a market capitalization of $29.58 billion, a PE ratio of -25.26 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period last year, the firm posted ($1.12) EPS. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, insider Xiaolin Wang sold 2,010 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $199,954.80. Following the completion of the transaction, the insider owned 116,063 shares in the company, valued at $11,545,947.24. This represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Stephen Michael Kelsey sold 4,302 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $427,962.96. Following the transaction, the insider directly owned 295,398 shares in the company, valued at approximately $29,386,193.04. The trade was a 1.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 64,592 shares of company stock valued at $6,488,732 over the last quarter. 8.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Indiana Trust & Investment Management Co purchased a new stake in Revolution Medicines in the fourth quarter valued at approximately $32,000. Global Retirement Partners LLC grew its position in shares of Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after acquiring an additional 361 shares during the last quarter. Torren Management LLC acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $33,000. Arax Advisory Partners acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $38,000. Finally, GAMMA Investing LLC raised its position in Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after purchasing an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.